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Objectives This study sought to report on the pathology of transcatheter aortic valves explanted at
early and late time points after transcatheter aortic valve implantation.
Background Information on pathological ﬁndings following transcatheter aortic valve implantation
is scarce, particularly late after transcatheter aortic valve implantation.
Methods This study included 20 patients (13 men, median age 80 years [interquartile range: 72 to
84] years) with previous transcatheter aortic valve implantation with a valve explanted at autopsy
(n  17) or surgery (n  3) up to 30 months after implantation (10 transapical and 10 transfemoral
procedures).
Results Structural valve degeneration was not seen, although ﬁbrous tissue ingrowth was observed
at later time points with minimal effects on cusp mobility in 1 case. Minor alterations in valve con-
ﬁguration or placement were observed in up to 50% of cases, but they were not accompanied by
substantial changes in valve function or reliably associated with chest compressions. Vascular or
myocardial injury was common, especially within 30 days of transcatheter aortic valve implantation
(about 69%), with the latter associated with left coronary ostial occlusion by calciﬁed native aortic
valve tissue in 2 cases. Mild to severe myocardial amyloidosis was present in nearly 33% of cases
and likely played a role in the poor outcome of 3 patients. Endocarditis, migration of the valve, and
embolization during the procedure led to surgical valve removal.
Conclusions Structural degeneration was not seen and minor alterations of valve conﬁguration or
placement did not affect valve function and were not reliably caused by chest compressions. Vascu-
lar or myocardial injury is very common early after transcatheter aortic valve implantation and myo-
cardial amyloidosis represents a relatively frequent potentially signiﬁcant comorbid condition.
(J Am Coll Cardiol Intv 2012;5:582–90) © 2012 by the American College of Cardiology Foundation
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583Transcatheter aortic valve implantation (TAVI) has been
established as an effective treatment for patients with severe
aortic valve stenosis who are not suitable for open-heart
surgery (1) or as an alternative treatment to open-heart
surgery in high-risk patients (2).
Mortality occurring 30 days after TAVI reflects mostly
procedure-related mortality (3,4), whereas later mortality
occurring from 30 days to 1 year after TAVI is mostly
caused by either progression of heart failure or the natural
course of comorbid conditions (3,5,6). Procedure-related
mortality decreases with increasing operator and center
experience (3). Later mortality, by contrast, decreases by
performing the procedure in lower-risk populations with
fewer comorbid conditions (5).
Very little information is currently available on the
pathological findings following TAVI (7). Post-mortem
studies in humans consist of 2 case reports (8,9) and a single
series of 7 post-mortem cases (10). These prior reports
primarily demonstrate findings early after valve implanta-
tion with only 1 reported case with late follow-up at 425
days (9). In this report, we describe pathological findings in
20 valves explanted at early, intermediate, and late time
points following TAVI.
Methods
Patients. All patients with prior TAVI who died and
underwent a post-mortem examination or who had a valve
surgically explanted at our institution were reviewed. Writ-
ten permission for pathological examination was obtained in
each case.
Valves and procedural approach. The Cribier-Edwards
alve (Edwards Lifesciences, Irvine, California), the proto-
ypic balloon-expandable prosthetic implant (11), is con-
tructed of a stainless steel frame with attached equine
ericardial leaflets and a fabric-sealing cuff. This was sub-
equently replaced with the Edwards Sapien valve (Edwards
ifesciences) with bovine pericardial leaflets and a longer
abric sealing cuff (12). The prosthetic valve is crimped onto
balloon catheter and introduced through a large sheath in
he femoral artery (transarterial) (13) or directly through the
eft ventricular apex using an intercostal incision (transapi-
al) (14). The prosthesis is placed inside the diseased native
ortic valve and the balloon expanded, displacing the native
usps.
Pathological analysis. Entire hearts (in case of an autopsy)
or the explanted transcatheter valves (in case of surgical
removal) were fixed in 10% buffered formalin and examined
by a cardiovascular pathologist (M.F.A.). Autopsy hearts
were examined by a stepwise approach to identify and
evaluate structural and nonstructural changes in the pros-
thesis, changes associated with the prosthesis or the proce-
dure, and other cardiac or vascular findings, in accordance
with accepted approaches for traditional prosthetic valves f(15) or recommendations for transcatheter valves (16).
Surgically excised transcatheter valves were examined in a
similar fashion.
For microscopic analysis, paraffin-embedded myocardium
was sectioned at 4 m and stained with hematoxylin and
osin, Masson trichrome (to identify fibrosis) (Ventana
edical Systems, Tucson, Arizona), Prussian blue (to
dentify iron) (Ventana Medical Systems), and Congo red
Ventana Medical Systems) and sulfated Alcian blue (to
dentify amyloid) (Acros Organics, Geel, Belgium, Fisher
cientific, Ottawa, Ontario, Canada). In selected patients
ith relevant rhythm disturbances and/or unexplained
eath, the region of the atrioventricular node and the bundle
ranches within the interventricular septum were micro-
copically examined. Valve cusps, when examined, were
ectioned at 4 m and stained with hematoxylin and eosin,
Movat pentachrome (Fisher Scientific; Sigma-Aldrich,
Oakville, Ontario, Canada; Acros Organics), and microbi-
ological stains, if appropriate.
Statistics. Statistical analyses were done using R Statistical Com-
uting for Mac OS (The R Foundation for Statistical Comput-
ng, Vienna, Austria). Data are presented as medians and inter-
uartile ranges, unless otherwise indicated. For each valve and
ardiac findings groups (structural
nd nonstructural changes/dys-
unction; prosthesis/procedure-
elated changes; and other cardiac
hanges), group comparison was
erformed using Kruskal-Willis
est. Significance was taken at
 0.05 level for all analyses.
esults
Patient characteristics. A total of 17 valves were examined
at autopsy (median age: 78 years, 10 men), including 6
Cribier-Edwards valves and 11 Edwards Sapien valves.
Access for implantation was nearly equivalent, either apical
(n  9) or transarterial (n  8), for the entire group. Three
valves were removed from patients at the time of open-heart
surgery (median age: 82 years, all men).
Time after implantation and cause of death. Of the 17
utopsy patients, median post-procedural survival was 5
ays (interquartile range: 2 to 25 days, range: 0 to 943 days).
atients were stratified into 3 temporal categories (16,17):
mmediate-early (7 days); intermediate (7 to 29 days); and
ate (30 days). Death occurred in 9 patients 7 days after
mplantation and was due to: cardiac causes (heart failure,
ajor arrhythmia, rupture of adjacent structures, left main
cclusion) in 5; cerebrovascular accident in 1; major bleed-
ng in 2; and sepsis in 1. In the intermediate group, cause of
eath was cardiac in 3 and sepsis in 1. After 30 days, 1
atient died because of an intracerebral bleed (on warfarin
Abbreviations
and Acronyms
CPR  cardiopulmonary
resuscitation
TAVI  transcatheter aortic
valve implantationor atrial fibrillation) and 3 because of progressive heart and
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584renal failure. All 3 surgically excised transcatheter valves
were removed more than 30 days after implantation, rang-
ing from 108 to 336 days after implantation (Table 1).
Structural and nonstructural prosthesis changes. The most
common structural change observed was a less than round
configuration that ranged from slightly oval to almost
D-shaped (Figs. 1 and 2). This finding occurred across all
temporal categories and, in some instances, was accompa-
nied by an apparent malalignment or malapposition of valve
cusps (cuspal tautness, laxity, and/or poor coaptation).
There were no macroscopic signs of cuspal degeneration
(calcifications or cuspal tears), or any evidence of fracture or
disruption of the metallic stent in any valve.
Fibrous tissue ingrowth was found in valves from patients
dying late after TAVI (Fig. 3) and ranged from minimal to
extensive where a thin layer of filmy fibrous tissue covered
Table 1. Patient Characteristics and Pathological Findings of
Autopsy Cases
Age (Yrs)
Time to Death
After Implantation Pathological Findings Access Route
Men
78 3 days Recent myocardial injury
Recent brain injury
Apical
87 5 days Coronary ostial occlusion
Recent myocardial injury
Arterial
57 5 days Heavily calciﬁed bicuspid
aortic valve
Recent brain injury
Apical
65 5 days Cuspal thrombosis
Recent myocardial injury
Arterial
80 6 days Recent myocardial injury
Recent brain injury
Apical
76 2 weeks Amyloidosis Arterial
77 28 days Possible hypertrophic
cardiomyopathy
Apical
73 1 month Arterial
89 20 months Fibrous tissue ingrowth
Amyloidosis
Arterial
85 24 months Fibrous tissue ingrowth
Recent brain injury
Arterial
Women
84 1 day Vascular injury
Recent myocardial injury
Apical
58 1 day Vascular injury
Recent myocardial injury
Apical
81 1 day Partial coronary ostial occlusion
Recent myocardial injury
Apical
80 5 days Recent myocardial injury
Amyloidosis
Apical
71 10 days Recent myocardial injury
Ischemic bowel
Apical
81 6 weeks Amyloidosis Apical
99 30 months Fibrous tissue ingrowth
Amyloidosis
Arterial
16 cases showed some degree of coronary artery disease (mild to severe); 13 cases had mitral
annular calcification; all 17 cases showed myocardial hypertrophy.approximately 80% to 90% of the inner aspect of the dmetallic stent (Fig. 4). Localized fibrous tissue ingrowth
onto the basal aspects of the cusps mildly reduced cuspal
mobility in 1 case (Fig. 1).
A probe-patent paravalvular defect was another relatively
frequent observation that spanned all temporal categories
(Fig. 3). Minor degrees of prosthesis malposition, using
relation of the inferior aspect of the prosthesis stent frame to
the insertion of the anterior leaflet of the mitral valve as a
guide, were also observed in several cases.
Small amounts of recent thrombotic material on the
ventricular and aortic aspects of the cusps (preferentially
near the commissural regions) and metallic stent were found
in 1 case in the immediate-early group. Histologically, the
thrombotic material was composed largely of fibrin and
platelets. Notably, echocardiography at the time of valve
implantation suggested thrombus on the guidewire and
possibly on the valve despite heparinization. There was no
evidence of thromboembolism at the time of autopsy,
however. Vegetations were not seen in any of the prostheses
from cases examined at autopsy.
Functional consequences of structural and nonstructural
prosthesis changes. Most patients demonstrated paravalvu-
ar aortic regurgitation, as assessed by echocardiography,
anging from trivial to moderate in severity. Structural and
onstructural prosthesis changes do not readily explain the
aravalvular regurgitation observed. Transvalvular aortic
egurgitation was not seen in the valve with fibrous tissue
ngrowth that mildly reduced cuspal mobility. Based on
ases with well-documented use of chest compressions
uring cardiopulmonary resuscitation (CPR) (n  8), an
equal number of cases with chest compressions were found
to be associated with altered valve shape (n  4) as
compared to those that were not (n  4). However,
dramatic changes in shape that were accompanied by
tautness of 1 valve cusp and laxity of others (Fig. 2B) did not
demonstrate significant alterations in valve function during
life.
Prosthesis- or procedure-associated changes. Most of these
ndings occurred primarily in immediate-early or interme-
iate periods after implantation with a more frequent
ccurrence in the immediate-early time frame (Fig. 5) (p 
.03). Myocardial injury in the form of contraction band
hange in isolated or clusters of cardiac myocytes or areas of
oagulative necrosis of myocardium was observed in more
han 50% of all cases with the greatest frequency of
ccurrence seen in patients dying in the immediate-early
eriod (Fig. 5). In select cases, acute injury of the conduct-
ng myocardium, especially the left bundle branch, was
bserved with evidence that both ischemic and direct
raumatic injury played a role. Most likely, any injuries
bserved arose from the valve or delivery system rather than
rom the guidewire.
Sections of healing transapical access sites showed evi-
ence of injured myocytes, accumulation of mesenchymal
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585cellular elements, hemorrhage, and small amounts of fibrous
connective tissue deposition.
Apparent obstruction of coronary ostia was observed
relatively frequently at autopsy examination, providing an
explanation for some of the myocardial injury observed
(Fig. 5). The most severe obstruction was observed in 2
cases in which a calcified and thickened native aortic valve
cusp caused complete or near complete obstruction of the
left coronary ostium. This was accompanied by hypotension
and showed significant ischemic myocardial injury in both.
The distance from the aortic annulus to the left coronary
ostium was relatively short in both patients: 8.5 and 9.5 mm,
respectively. The left sinuses of Valsalva were of normal size
and not particularly shallow.
Procedural-related injuries to vascular or other cardiac
structures were seen in a small number of cases (Fig. 5) that
when present resulted in catastrophic effects and rapidly led
to very poor outcomes. Traumatic disruption of the annular
region of the aorta occurred in 1 patient in whom the
smallest available prosthesis (23-mm diameter) was signif-
icantly larger than the relatively small (18 mm) and heavily
calcified annulus. In a second patient with severe mitral
annular calcification and substantially reduced leaflet mo-
bility, a 2-cm tear involving the basal aspects of the anterior
mitral leaflet and adjacent outflow tract (Fig. 6) was created
during the procedure that resulted in communication be-
tween the left ventricle and atrium and hemodynamic
Figure 1. Bar Graph Illustrating Relative Frequency of Structural Prosthesi
Expressed as percentages. n  4 to 9 per group.collapse. Transapical access was associated with massivebleeding followed by death due to multiorgan failure at day
5 in another patient.
Other cardiac and vascular ﬁndings. All patients had evi-
ence of increased cardiac mass or hypertrophy. Many
atients also had coronary atherosclerosis and its manifes-
ations, including healed myocardial infarction and proce-
ures such as coronary artery bypass surgery and/or percu-
aneous coronary intervention. Mitral annular calcification
as also a common finding whose severity potentially played
role in some of the deleterious outcomes described
reviously. Myocardial amyloidosis was present in nearly
ne-third of all autopsy cases (5 cases, age 60 to 99 years)
nd ranged in severity from relatively mild to extensive and
evere. Less severe involvement by amyloid was likely an
ncidental finding in 2 patients, but where it was severe, it
ay have contributed to death due to progressive heart
ailure leading to death at 40, 608, and 943 days after
urgery.
Findings in surgically excised transcatheter valves. Reasons
for surgical valve explantation were: embolization at the
time of the procedure with the valve deployment in the
aortic arch and definitive surgical open-heart aortic valve
replacement with explantation of the embolized valve (at
day 108); low implantation with gradual migration to the
left ventricular outflow tract resulting in severe aortic
regurgitation (at day 109); and endocarditis (at 336 days). In
the latter case, the patient developed Streptococcus angiosus
nges According to Time After Implantations Chaendocarditis of mitral and transcatheter aortic valves 6
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586weeks after a dental procedure that took place without
endocarditis prophylaxis. The endocarditis spread to the
mitral valve at the contact point of the aortic valve prosthesis
with the anterior mitral leaflet leading to a perforation and
regurgitation.
Discussion
As a relatively new interventional procedure, detailed path-
ological examination of autopsy or surgical material from
patients undergoing transcatheter implantation is critical to
the ongoing evolution and improvement of this approach to
treatment of aortic valve disease. Results of the present
B
A
Figure 2. Altered Transcatheter Aortic Valve Configuration
Noncircular conﬁguration of a transcatheter valve removed from the heart
at autopsy (A) and cuspal malalignment (tautness of one cusp, arrow) in a
transcatheter valve with dramatic alterations in conﬁguration (B).investigation provide important insights into the changes inthe transcatheter valves, mechanisms, and functional con-
sequences of changes observed in the prostheses; emphasize
key pathologies related to the transcatheter valve implanta-
tion procedure; and serve to highlight the potential signif-
icance of comorbidities in this patient population.
Structural and nonstructural prosthesis changes. Current
surgical bioprostheses are relatively durable, although struc-
tural degeneration and failure can be anticipated to occur 5
to 20 years after implantation (18,19) with minimal histo-
logical degeneration seen up to 6 years after implantation
(20). In surgical bioprostheses, the major cause of failure is
related to calcification and tears of valve cusps, resulting in
regurgitation or stenosis (15,21). It is reassuring that we did
not observe significant structural valve failure in any case,
even up to 943 days after implantation. Variable degrees of
fibrous tissue ingrowth were observed late after implantation
with some localized involvement of valve cusps resulting in
a mild reduction in cuspal mobility but had no impact on
measurable valve function. Given its well-recognized occur-
rence in surgical bioprosthesis (15), it is highly likely that
more extensive fibrous tissue ingrowth will occur over time
in some prostheses and lead to prosthesis dysfunction,
which most likely can be treated by valve-in-valve implan-
tation (22).
A less than round configuration of the stent frame was a
relatively common observation, and the degree of noncircu-
lar configuration varied substantially. We cannot speculate
on the reason for stent eccentricity, except for CPR with
chest compressions as a possible explanation in patients
dying after transcatheter valve implantation. However, a
consistent and significant relationship between a noncircular
configuration of the stent frame and CPR with chest
compressions was not observed. This does not rule out the
possibility that CPR with chest compressions may cause
deformation in selected patients. The finding of deformed
stent frames in this post-mortem study stands in contrast to
our finding on computed tomography scans, on which
circular stents were found, 3 years or more after transcath-
eter valve implantation (23). Chest compressions during
CPR might explain this discrepancy in part but only in
selected cases. Whether such deformed stent frames, even
when mild, increase shear stress, thereby accelerating struc-
tural valve degeneration needs further investigation (24,25).
Thrombosis and thromboembolic complications occur
less often in association with bioprostheses as compared to
mechanical valves (26). Thrombus was uncommon in our
series, with significant thrombus evident in only 1 patient in
whom intraprocedural heparinization may have been sub-
therapeutic. Nevertheless, post-procedural thromboembolic
stroke remains a concern, and most groups use long-term
aspirin and clopidogrel for 1 to 6 months (27). The ideal
antithrombotic regimen is yet to be determined (28).
Surgical bioprostheses are said to be associated with a 4%
10-year risk for endocarditis (29). Mechanical valves are most
leaﬂe
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587often associated with localization of infection at the sewing
ring, whereas infection of bioprosthetic valves is more often
localized on the valve cusps (15). Infection of our single
transcatheter valve was rather diffuse, involving the sewing skirt
as well as the valve cusps and was accompanied by infection
and perforation of the mitral leaflet (30). Piazza et al. (31)
reported a similar case in a low implanted CoreValve prosthesis
(Medtronic, Inc., Minneapolis, Minnesota).
Figure 3. Bar Graph Illustrating Relative Frequency of Nonstructural Prosth
Expressed as percentages. n  4 to 9 per group. AMVL  anterior mitral valve
Figure 4. Fibrous Tissue Ingrowth
Photograph showing ﬁbrous tissue ingrowth on the stent frame of a trans-
catheter valve (arrow).Functional consequence of prosthesis changes. Mild to
moderate paravalvular aortic regurgitation after TAVI is
common, as was observed in patients in our study, although
the clinical relevance of this degree of paravalvular regurgi-
tation is uncertain (32–34). Despite a significantly higher
incidence of trivial to moderate paravalvular leaks in patients
after transcatheter valve implantation as compared to sur-
gical patients, transcatheter valve patients have significantly
better hemodynamics and improvement of left ventricular
function (35–37). Whether paravalvular leaks after TAVI
result in (clinically relevant) hemolysis (as described from
surgical collectives (38)) needs further investigation.
Of interest is the finding that the presence of a noncir-
cular shape of the stent frame, mild degrees of malalignment
or malposition of the transcatheter valve, or presence of a
probe patent paravalvular defect had no significant or
consistent association with severity of transvalvular or para-
valvular aortic regurgitation during life. Thus, mild altera-
tions in configuration or placement of transcatheter pros-
thetic aortic valves, as observed at autopsy, do not appear to
adversely affect function.
Prosthesis- and procedure-associated ﬁndings. Recent myo-
cardial injury was a relatively frequent observation in our
series of patients, especially in those dying in the
immediate-early time period after implantation. Left
coronary ostial obstruction was likely causative in 2
patients and was associated with low origins of the left
hanges According to Time After Implantation
t.esis Ccoronary artery and bulky, calcified native cusps in both
; BB 
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588cases (Fig. 7). Another known risk factor for coronary
ostial obstruction is a narrow aortic root with shallow
aortic sinuses (39). This complication has been described
in 0.6% of cases in a recent large registry (27), suggesting
that multimodality screening (40) may be important.
Obstruction of coronary arteries can be predicted during
balloon valvuloplasty with aortography during balloon
inflation. If coronary obstruction occurs during implan-
tation, early clinical signs include hypotension and severe
hypokinesis on echocardiography (41). Management in-
Figure 5. Bar Graph Illustrating Relative Frequency of Procedure-Associate
Expressed as percentages. n  4 to 9 per group. AVN  atrioventricular node
Figure 6. Mitral Valve Injury With Left Ventricle and
Left Atrial Communication
Defect (arrow) in the anterior leaﬂet of a mitral valve with severe calciﬁca-
tion of its annulus (double arrow) that led to a communication between
the left ventricle and the left atrium.cludes prompt cardiopulmonary support, coronary an-
giography, and, in most cases, urgent coronary revascu-
larization (39,42,43).
New onset of heart block can occur following transcath-
eter valve implantation. The incidence of heart block is
reportedly lower with the balloon-expandable Edwards
valve, used in this series, as compared to the self-expanding
CoreValve (3,27,44). Based on findings in select cases where
the conduction system was examined, it appears that a
combination of direct traumatic effects to the bundle branch
nges According to Time After Implantation
bundle branch; IVS  interventricular septum; PB  penetrating bundle.
Figure 7. Left Coronary Ostial Obstruction
Photograph showing a bulky, calciﬁed native valve cusp ﬁlling the sinus
region of the aorta (arrow) to cause obstruction of the left coronaryd Chaostium.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 5 , 2 0 1 2 Nietlispach et al.
MA Y 2 0 1 2 : 5 8 2 – 9 0 Transcatheter Valve Pathology
589system and ischemic injury occurring because of pressure-
induced alterations of flow in coronary septal arteries in the
interventricular septum are potential contributing factors.
Other cardiac and vascular ﬁndings. One accompanying
finding that warrants special mention is myocardial amy-
loidosis, which occurred in nearly one-third of all cases
studied. Senile systemic amyloidosis is very common in
elderly people, reportedly present in 25% of individuals over
the age of 80 years, and often goes unrecognized (45).
Whereas patients with cardiac amyloidosis can successfully
undergo surgical procedures, operative and post-operative
problems associated with anesthesia are well described
(46–48). As such, recognition of the possible presence of
the condition and involvement of anesthetists familiar with
cardiac anesthesia in this setting are important. Moreover,
the transcatheter valve approach, as compared to open-heart
valvular replacement with cardiopulmonary bypass, may be
the technique of choice in this patient population.
Conclusions
Significant structural degeneration of transcatheter valves
does not occur up to 30 months after implantation, and
minor alterations in valve configuration or placement do not
appear to be associated with substantial changes in function
of the valves during life when assessed by echocardiography.
Chest compressions during CPR may cause alterations in
configuration of valves but only in a minority of cases.
Myocardial injury is common early after the implantation
procedure with coronary ostial obstruction by a thick,
calcified native aortic valve cusp in the setting of a shallow
coronary sinus, narrow aortic root, and/or low origin of the
ostium likely a causative factor in some. Finally, myocardial
amyloidosis is common in this patient population and
warrants recognition because of its potential to have dele-
terious effects.
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